I will add to that.
I believe the committee members have already received two letters, which have been translated. A third one is coming. A fourth one has already been received but is being translated. It is expected. I raise this not to say these letters aren't welcome but that they open up a bit of a concern. I don't think we're suggesting that anyone who writes a letter should be in a position to come to that meeting. We have their written testimony. I want to flag that. It doesn't end with the first two we've received. Others are coming as well.
I'm not breaking any confidence if I say this: The contact I had today was looking to offer another opinion—the case for disclosure. It might be best to focus on the pharmaceuticals. Of course, that is a question for the committee.
I'll go back to you, Mr. Fragiskatos.